marked.bio

Company

BeBetter Med

2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 3 trials shown

  1. Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

    Recruiting Phase 2 BeBetter Med Started 2024Primary completion 2027-06 NCT06514027

    BEBT-109 Capsulespemetrexedcarboplatincisplatin

    Patients may have only EGFR exon 20 insertion mutations or may also have other EGFR or HER2 mutations;

    EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutationNon Small Cell Lung Cancer

  2. Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

    Recruiting Phase 2 BeBetter Med Started 2022Primary completion 2025-12 NCT06706713

    BEBT-109 Capsule

    Written test reports confirm the occurrence of EGFR exon 20 insertion mutations.

    EGFR exon 20 insertionNon-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation